Chronic Hepatitis B Drug Development Summit

Published on 09/04/2021

5-6 May, 2021

Pietro Scalfaro, our CMO, will present clinical results of our lead compound Vonafexor at the Chronic Hepatitis B Drug Development Summit : “Targeting the Farnesoid X Receptor for the Treatment of Chronic Hepatitis B”.

This Summit is the first-ever dedicated digital industry forum dedicated exclusively to the frontier of drug development in Chronic HBV. The two-day program explores the full spectrum of antiviral & immunomodulatory agents being investigated to achieve a functional cure in chronic HBV infection & mitigate related conditions such as fibrosis, cirrhosis, & hepatocellular carcinoma.

More details here: https://chronic-hbv-summit.com/

Read next in 'Events'

• FEDERG meeting - 10 years, 2024
• The 2024 international workshop on Alport syndrome
• Alport Connect 2024, la rencontre annuelle américaine avec les patients atteints du syndrome d’Alport
• ASN Kidney Week 2024
• ASN Kidney Week 2024